Anzeige
Mehr »
Freitag, 14.08.2026 - Börsentäglich über 12.000 News
Die Bohrungen sind fast abgeschlossen. Was jetzt kommt, könnte noch wichtiger sein
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PUQT | ISIN: DK0061155009 | Ticker-Symbol:
1-Jahres-Chart
PHARMA EQUITY GROUP A/S Chart 1 Jahr
5-Tage-Chart
PHARMA EQUITY GROUP A/S 5-Tage-Chart

Aktuelle News zur PHARMA EQUITY GROUP Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
09:50Pharma Equity Group A/S: Pharma Equity Group consolidated Interim Report 1 January - 30 June 2026146Consolidated Interim Report 1 January - 30 June 202614 August 2025Announcement no. 9 On 14 August 2026, the Board of Directors and the Executive Board of Pharma Equity Group A/S ("PEG", "The Company"...
► Artikel lesen
12.06.Pharma Equity Group A/S: Pharma Equity Group prevails in international arbitration proceedings and is awarded EUR 10.5 million excluding interest and costs36612 June 2026 Announcement no. 8 Pharma Equity Group prevails in international arbitration proceedings and is awarded EUR 10.5 million excluding interest and costs Pharma Equity Group A/S ("PEG"...
► Artikel lesen
PHARMA EQUITY GROUP Aktie jetzt für 0€ handeln
11.05.Pharma Equity Group A/S: Pharma Equity Group's subsidiary Reponex takes key step forward in Inflammatory Bowel Disease with upcoming European patent grant147Pharma Equity Group's subsidiary Reponex takes key step forward in Inflammatory Bowel Disease with upcoming European patent grant May 11, 2026Announcement no. 7 Pharma Equity Group A/S today announces...
► Artikel lesen
28.04.Pharma Equity Group A/S: The Board of Directors' resolution on the issuance of convertible loans1
17.04.Proceedings of the Annual General Meeting of Pharma Equity Group A/S189Proceedings of the Annual General Meeting of Pharma Equity Group A/S 17 April 2026Company Announcement no. 5 Pharma Equity Group A/S held its annual general meeting on 16 April 2026 at 3:30 pm CEST...
► Artikel lesen
25.03.Notice convening the annual general meeting in Pharma Equity Group A/S1
25.03.Pharma Equity Group A/S - Annual Report 202519825 March 2026 Announcement no. 3 Pharma Equity Group A/S - Annual Report 2025 Pharma Equity Group A/S - Annual Report 2025 - Highlights of the year Today, the Board of Directors of Pharma Equity Group...
► Artikel lesen
26.02.Pharma Equity Group A/S: SUPPLEMENTARY INFORMATION (CORRECTIVE INFORMATION) TO THE ANNUAL REPORT 2024 AND THE INTERIM REPORT FOR H1 20252
29.12.25Pharma Equity Group A/S: Pharma Equity Group - Strategic update and adjustment of expectations314Pharma Equity Group - Strategic update and adjustment of expectations Copenhagen, 29 December 2025 Company Announcement no. 16 Pharma Equity Group A/S ("PEG" or the "Company") hereby provides a strategic...
► Artikel lesen
10.12.25Pharma Equity Group A/S: Pharma Equity Group executes on the Company's new strategy: Enters into Letter of Intent to acquire the MedTech company Otiom A/S205Pharma Equity Group executes on the Company's new strategy: Enters into Letter of Intent to acquire the MedTech company Otiom A/S Copenhagen, 10 December 2025 Company Announcement no. 15 Pharma Equity...
► Artikel lesen
03.12.25Pharma Equity Group A/S' agreement with Danske Bank as liquidity provider will terminate on 1 January 2026321Pharma Equity Group A/S' agreement with Danske Bank as liquidity provider will terminate on 1 January 2026 3 December 2025 Company Announcement no. 14 Pharma Equity Group A/S ("PEG") announces that...
► Artikel lesen
01.09.25Pharma Equity Group A/S: Pharma Equity Group's subsidiary, Reponex Pharmaceuticals A/S, receives regulatory approval to initiate pivotal clinical trial with RNX-011 for life-threatening peritonitis432Pharma Equity Group's subsidiary, Reponex Pharmaceuticals A/S, receives regulatory approval to initiate pivotal clinical trial with RNX-011 for life-threatening peritonitis Copenhagen, September...
► Artikel lesen
12 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1